Arcutis Biotherapeutics (ARQT) Stock Forecast, Price Target & Predictions
ARQT Stock Forecast
Arcutis Biotherapeutics stock forecast is as follows: an average price target of $31.00 (represents a 108.61% upside from ARQT’s last price of $14.86) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
ARQT Price Target
The average price target for Arcutis Biotherapeutics (ARQT) is $31.00 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $51.00 to $18.00. This represents a potential 108.61% upside from ARQT's last price of $14.86.
ARQT Analyst Ratings
According to 4 Wall Street analysts, Arcutis Biotherapeutics's rating consensus is 'Buy'. The analyst rating breakdown for ARQT stock is 0 'Strong Buy' (0.00%), 3 'Buy' (75.00%), 0 'Hold' (0.00%), 1 'Sell' (25.00%), and 0 'Strong Sell' (0.00%).
Arcutis Biotherapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 15, 2024 | Serge Belanger | Needham | $18.00 | $8.13 | 121.40% | 21.13% |
| May 15, 2024 | Uy Ear | Mizuho Securities | $18.00 | $8.13 | 121.40% | 21.13% |
| Jan 02, 2024 | Mizuho Securities | $8.00 | $3.43 | 133.24% | -46.16% | |
| Dec 13, 2022 | Morgan Stanley | $51.00 | $16.58 | 207.60% | 243.20% | |
| Apr 27, 2022 | Eric Cha | Goldman Sachs | $37.00 | $19.61 | 88.63% | 148.99% |
The latest Arcutis Biotherapeutics stock forecast, released on May 15, 2024 by Serge Belanger from Needham, set a price target of $18.00, which represents a 121.40% increase from the stock price at the time of the forecast ($8.13), and a 21.13% increase from ARQT last price ($14.86).
Arcutis Biotherapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 3 |
| Avg Price Target | - | - | $14.67 |
| Last Closing Price | $14.86 | $14.86 | $14.86 |
| Upside/Downside | -100.00% | -100.00% | -1.28% |
In the current month, the average price target of Arcutis Biotherapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Arcutis Biotherapeutics's last price of $14.86. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 28, 2024 | Needham | Buy | Buy | Hold |
| Aug 28, 2024 | Jefferies | Underperform | Underperform | Hold |
| Aug 28, 2024 | Jefferies | Buy | Initialise | |
| Aug 15, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Jul 10, 2024 | Needham | Buy | Buy | Hold |
| May 15, 2024 | Needham | Buy | Buy | Hold |
| Apr 12, 2024 | Needham | Buy | Buy | Hold |
| Apr 12, 2024 | Mizuho Securities | Underperform | Underperform | Hold |
| Dec 13, 2022 | Morgan Stanley | Overweight | Overweight | Hold |
| Apr 26, 2022 | Zacks Investment Research | Sell | Downgrade |
Arcutis Biotherapeutics's last stock rating was published by Needham on Aug 28, 2024. The company gave ARQT a "Buy" rating, the same as its previous rate.
Arcutis Biotherapeutics Financial Forecast
Arcutis Biotherapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $13.53M | $38.11M | $5.19M | $2.78M | $2.96M | $725.00K |
| Avg Forecast | $92.00M | $72.64M | $64.05M | $56.26M | $54.72M | $37.62M | $29.09M | $15.18M | $11.41M | $32.91M | $4.60M | $3.14M | $614.29K | $614.29K |
| High Forecast | $96.22M | $75.98M | $66.99M | $57.53M | $55.59M | $39.34M | $29.09M | $15.87M | $11.93M | $34.43M | $4.81M | $3.28M | $642.49K | $614.29K |
| Low Forecast | $88.74M | $70.07M | $61.78M | $55.00M | $53.84M | $36.28M | $29.09M | $14.64M | $11.00M | $31.75M | $4.44M | $3.03M | $592.51K | $614.29K |
| # Analysts | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | 1.19% | 1.16% | 1.13% | 0.89% | 4.82% | 1.18% |
Arcutis Biotherapeutics's average Quarter revenue forecast for Mar 24 based on 1 analysts is $15.18M, with a low forecast of $14.64M, and a high forecast of $15.87M. ARQT's average Quarter revenue forecast represents a 12.19% increase compared to the company's last Quarter revenue of $13.53M (Dec 23).
Arcutis Biotherapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | $-60.78M | $-34.18M | $-66.76M | $-73.06M | $-65.10M | $-102.53M |
| Avg Forecast | $18.40M | $14.53M | $12.81M | $11.25M | $10.94M | $7.52M | $5.82M | $3.03M | $2.28M | $6.58M | $919.68K | $627.50K | $122.86K | $122.86K |
| High Forecast | $19.24M | $15.20M | $13.40M | $11.51M | $11.12M | $7.87M | $5.82M | $3.17M | $2.39M | $6.89M | $961.91K | $656.31K | $128.50K | $122.86K |
| Low Forecast | $17.75M | $14.01M | $12.36M | $11.00M | $10.77M | $7.26M | $5.82M | $2.93M | $2.20M | $6.35M | $887.07K | $605.25K | $118.50K | $122.86K |
| Surprise % | - | - | - | - | - | - | - | - | -26.64% | -5.19% | -72.59% | -116.43% | -529.92% | -834.53% |
undefined analysts predict ARQT's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Arcutis Biotherapeutics's previous annual EBITDA (undefined) of $NaN.
Arcutis Biotherapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - | $-66.28M | $-44.77M | $-70.99M | $-79.74M | $-75.61M | $-110.67M |
| Avg Forecast | $-31.08M | $-29.21M | $-34.80M | $-41.64M | $-35.05M | $-51.85M | $-64.20M | $-85.15M | $-97.22M | $-113.58M | $-155.39M | $-159.69M | $-215.20M | $-213.78M |
| High Forecast | $-29.64M | $-27.86M | $-33.20M | $-37.29M | $-27.54M | $-49.46M | $-61.24M | $-81.22M | $-71.79M | $-108.35M | $-148.23M | $-152.33M | $-205.28M | $-213.78M |
| Low Forecast | $-32.93M | $-30.96M | $-36.88M | $-45.99M | $-40.06M | $-54.95M | $-68.03M | $-90.23M | $-121.15M | $-120.36M | $-164.67M | $-169.22M | $-228.04M | $-213.78M |
| Surprise % | - | - | - | - | - | - | - | - | 0.68% | 0.39% | 0.46% | 0.50% | 0.35% | 0.52% |
Arcutis Biotherapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ARQT's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Arcutis Biotherapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - | $48.48M | $47.59M | $45.96M | $42.92M | $37.02M | $35.47M |
| Avg Forecast | $721.98M | $570.05M | $502.63M | $441.53M | $429.38M | $295.20M | $228.28M | $119.09M | $89.53M | $258.30M | $36.09M | $24.62M | $4.82M | $4.82M |
| High Forecast | $755.13M | $596.23M | $525.71M | $451.45M | $436.24M | $308.76M | $228.28M | $124.56M | $93.64M | $270.16M | $37.74M | $25.75M | $5.04M | $4.82M |
| Low Forecast | $696.38M | $549.84M | $484.81M | $431.62M | $422.52M | $284.73M | $228.28M | $114.87M | $86.35M | $249.14M | $34.81M | $23.75M | $4.65M | $4.82M |
| Surprise % | - | - | - | - | - | - | - | - | 0.54% | 0.18% | 1.27% | 1.74% | 7.68% | 7.36% |
Arcutis Biotherapeutics's average Quarter SG&A projection for Mar 24 is $119.09M, based on 1 Wall Street analysts, with a range of $114.87M to $124.56M. The forecast indicates a 145.66% rise compared to ARQT last annual SG&A of $48.48M (Dec 23).
Arcutis Biotherapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - | $-0.72 | $-0.73 | $-1.16 | $-1.30 | $-1.24 | $-1.94 |
| Avg Forecast | $-0.25 | $-0.23 | $-0.28 | $-0.34 | $-0.28 | $-0.42 | $-0.52 | $-0.69 | $-0.78 | $-0.91 | $-1.25 | $-1.28 | $-1.73 | $-1.73 |
| High Forecast | $-0.24 | $-0.22 | $-0.27 | $-0.30 | $-0.22 | $-0.40 | $-0.49 | $-0.65 | $-0.58 | $-0.87 | $-1.19 | $-1.23 | $-1.65 | $-1.73 |
| Low Forecast | $-0.26 | $-0.25 | $-0.30 | $-0.37 | $-0.32 | $-0.44 | $-0.55 | $-0.73 | $-0.97 | $-0.97 | $-1.32 | $-1.36 | $-1.83 | $-1.73 |
| Surprise % | - | - | - | - | - | - | - | - | 0.92% | 0.80% | 0.93% | 1.01% | 0.72% | 1.12% |
According to undefined Wall Street analysts, Arcutis Biotherapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ARQT previous annual EPS of $NaN (undefined).
Arcutis Biotherapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| SPRO | Spero Therapeutics | $1.04 | $10.00 | 861.54% | Buy |
| INZY | Inozyme Pharma | $2.94 | $16.00 | 444.22% | Buy |
| XFOR | X4 Pharmaceuticals | $0.74 | $3.67 | 395.95% | Buy |
| ABOS | Acumen Pharmaceuticals | $1.96 | $7.00 | 257.14% | Buy |
| CHRS | Coherus BioSciences | $1.71 | $6.00 | 250.88% | Hold |
| TERN | Terns Pharmaceuticals | $6.80 | $18.67 | 174.56% | Buy |
| ERAS | Erasca | $2.63 | $6.00 | 128.14% | Buy |
| ARQT | Arcutis Biotherapeutics | $14.86 | $31.00 | 108.61% | Buy |
| APLS | Apellis Pharmaceuticals | $34.53 | $70.80 | 105.04% | Buy |
| AMLX | Amylyx Pharmaceuticals | $4.28 | $8.25 | 92.76% | Buy |
| DAWN | Day One Biopharmaceuticals | $12.64 | $24.00 | 89.87% | Buy |
| BOLT | Bolt Biotherapeutics | $0.54 | $1.00 | 85.19% | Hold |
| DSGN | Design Therapeutics | $6.25 | $9.67 | 54.72% | Buy |
| MIRM | Mirum Pharmaceuticals | $42.65 | $57.00 | 33.65% | Buy |